Previous 10 | Next 10 |
2023-05-28 10:15:00 ET The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. But even in this environment, some equities should perform just fine -- or even better. Let's look...
2023-05-27 06:14:00 ET You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects. Three Fool.com contributors identified no-brainer healthcare stocks to buy for under $100. Here's why they chose CRISPR Therapeu...
2023-05-25 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedi...
2023-05-24 16:23:42 ET Summary Vertex Pharmaceuticals Incorporated data readout from a phase 3 program, using VX-548 for the treatment of patients with acute pain, could be released by the 1st half of 2024. Proof of concept, using VX-548 for the treatment of patients with acute pa...
2023-05-24 07:24:00 ET Novo Nordisk ( NVO ) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced Wednesday. Under the partnership, two companies will focus ...
2023-05-21 09:30:00 ET On May 10, Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) made two sales of CRISPR Therapeutics (NASDAQ: CRSP) stock, dumping more than 249,500 shares. Given that the biotech looks to be on the cusp of commercializing its first medicine, the timing o...
2023-05-19 10:32:26 ET Summary Regulatory marketing authorization filings for its lead drug candidate were submitted to U.S. and international bodies. Three weeks separate the U.S. filings from that of a competitor's product. Delays could be costly, surrendering first-to-marke...
2023-05-18 15:45:39 ET Summary Patients are currently being enrolled by CRISPR Therapeutics AG in a potentially pivotal single-arm phase 2 study using CTX-110 for the treatment of patients with large B-cell lymphoma. CTX-110 was successful in patients with LBCL in phase 1 CARBON s...
2023-05-17 00:15:00 ET Summary One of the most promising applications of AI in drug discovery is in the identification of new drug targets (AI can be used to discover new drugs). The ability to analyze large amounts of molecular and genomic data quickly and efficiently is somethin...
2023-05-16 05:41:00 ET So far, 2023 is turning out to be a pretty good year for growth stock investors in general. The Vanguard Growth ETF has already gained 19% in 2023. For investors with either CRISPR Therapeutics (NASDAQ: CRSP) or Nanox (NASDAQ: NNOX) in their po...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: